AMNEAL PHARMACEUTICALS ($AMRX) posted quarterly earnings results on Tuesday, August 5th. The company reported earnings of $0.25 per share, beating estimates of $0.18 by $0.07. The company also reported revenue of $724,510,000, missing estimates of $759,452,220 by $-34,942,220.
You can see Quiver Quantitative's $AMRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AMNEAL PHARMACEUTICALS Insider Trading Activity
AMNEAL PHARMACEUTICALS insiders have traded $AMRX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:
- TUSHAR BHIKHUBHAI PATEL sold 5,000,000 shares for an estimated $41,750,000
- GAUTAM PATEL has made 0 purchases and 5 sales selling 263,574 shares for an estimated $2,206,490.
- ANDREW S BOYER (Executive Vice President) sold 125,000 shares for an estimated $1,111,250
- TASOS KONIDARIS (Executive Vice President & CFO) sold 100,000 shares for an estimated $891,000
- JASON B. DALY (EVP, Chief Legal Officer) has made 0 purchases and 2 sales selling 90,000 shares for an estimated $792,159.
- EMILY PETERSON ALVA sold 80,000 shares for an estimated $712,000
- JOHN KIELY sold 50,000 shares for an estimated $379,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMNEAL PHARMACEUTICALS Hedge Fund Activity
We have seen 137 institutional investors add shares of AMNEAL PHARMACEUTICALS stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HENNESSY ADVISORS INC removed 1,499,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,130,146
- CITADEL ADVISORS LLC removed 1,488,939 shares (-16.6%) from their portfolio in Q1 2025, for an estimated $12,477,308
- PHOCAS FINANCIAL CORP. added 1,057,489 shares (+523.8%) to their portfolio in Q1 2025, for an estimated $8,861,757
- WOODLINE PARTNERS LP added 937,035 shares (+165.2%) to their portfolio in Q1 2025, for an estimated $7,852,353
- VANGUARD GROUP INC added 920,758 shares (+6.2%) to their portfolio in Q1 2025, for an estimated $7,715,952
- ACADIAN ASSET MANAGEMENT LLC added 880,471 shares (+51.3%) to their portfolio in Q1 2025, for an estimated $7,378,346
- MILLENNIUM MANAGEMENT LLC added 762,842 shares (+57.6%) to their portfolio in Q1 2025, for an estimated $6,392,615
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMNEAL PHARMACEUTICALS Government Contracts
We have seen $173,571 of award payments to $AMRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- XYREM (SODIUM OXYBATE) ORAL SOLUTION.: $173,571
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AMNEAL PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AMRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 03/03/2025
- JP Morgan issued a "Overweight" rating on 02/24/2025
To track analyst ratings and price targets for AMNEAL PHARMACEUTICALS, check out Quiver Quantitative's $AMRX forecast page.
AMNEAL PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AMRX recently. We have seen 2 analysts offer price targets for $AMRX in the last 6 months, with a median target of $11.5.
Here are some recent targets:
- Balaji Prasad from Barclays set a target price of $11.0 on 03/03/2025
- Chris Schott from JP Morgan set a target price of $12.0 on 02/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
